Special Issue "Peptide Therapeutics"
Deadline for manuscript submissions: closed (10 October 2017).
2. CIBER-BBN (Networking Centre on Bioengineering, Biomaterials and Nanomedicine) and Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain
Interests: all aspects of the synthesis of peptides and their application in therapy
Special Issues and Collections in MDPI journals
Special Issue in Molecules: Chemical Protein and Peptide Synthesis
Special Issue in Molecules: Combinatorial Synthesis
Special Issue in Marine Drugs: Selected Papers from the 14th International Symposium on Marine Natural Products
Special Issue in Molecules: Organic Synthesis on Solid Phase
Special Issue in Methods and Protocols: Feature Papers
Special Issue in Biomedicines: Peptides of Natural Origins as Leads for Drug Discovery: From Native Structures to Peptidomimetics, Peptide-Conjugates, and Peptide-Nanoparticles
Special Issue in Antibiotics: Antibiotic Resistance: From the Bench to Patients
Special Issue in Methods and Protocols: Feature Issue on the Development of Novel Cutting Edge Protocols
Special Issue in Microorganisms: New Cationic Antimicrobial Peptides
Special Issue in Methods and Protocols: Feature Papers 2021
Special Issue in Applied Sciences: Latest Advances on Synthesis, Purification, and Characterization of Peptides and Their Applications
Interests: peptides; solid-phase synthesis; cell penetrating peptides; antimicrobial peptides; oligonucleotides; peptide nucleic acids; drug discovery; peptide–drug conjugates
Special Issues and Collections in MDPI journals
During the last few years, the role of peptides in the drug discovery arena have been increased enormously, and, every year, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approve several of these chemical entities as new drugs. It is interesting to analyze the peptide–amino-acid-based drugs accepted by the FDA in 2016 (Molecules, 22, 368; doi:10.3390/molecules22030368 (2017)). Adlyxin (Lixisenatide) is a 44-amino acid peptide, which can be considered as a small protein prepared by chemical methods, is a glucagon-like peptide (GLP-1). At the opposite end of the complexity point of view, Xiidra (Lifitegrast), which is recommended for dry eye disease, in an acyl dipeptide formed by two non-natural amino acids. During 2016, the FDA approved two amino acid derivatives: Briviact (Brivaracetam) and Auxim (Fluciclovine f-18) for epilepsy and as a diagnostic agent in Positron emission tomography (PET) imaging for cancer. This is an excellent example of the diversity of our field, in terms of both chemical structure and target therapeutics.
However, even more important than the number of chemical entities accepted by agencies is the large number of peptides that are presently in clinical trials. Furthermore, peptides, in addition to being an active pharmaceutical ingredient (API), are being used as shuttles to overcome some barriers, and are also used as linkers to bind together two moieties in the same drug, as occurs in antibody drug conjugates (ADC).
This Special Issue of Molecules aims to reflect the wonderful world surrounding peptides as therapeutics.
Prof. Fernando Albericio
Prof. Beatriz G. de la Torre
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- therapeutic peptides
- solid-phase peptide synthesis
- antimicrobial peptides
- peptides and Alzheimer disease
- peptides and metabolic syndrome
- peptides and cancer
- peptides as shuttles
- peptide based drug delivery
- peptide based vaccines
- peptides drug conjugates